The ABLE platform First author Jiuyun Shi holds a living bioelectronics device that integrates flexible electronic sensors, hydrogel and living cells to monitor and heal skin conditions. (Courtesy: ...

Reaserchers have created a prototype for what they call 'living bioelectronics': a combination of living cells, gel, and electronics that can integrate with living tissue. Tests in mice found that the ...

BioElectronics Corp., a manufacturer of non-invasive electroceutical devices in Frederick, announced that it has received market clearance from the U.S. Food and Drug Administration for its medical ...

The review emphasizes the switching mechanisms of organic neuromorphic materials. In addition to these switching mechanisms, the capabilities of organic neuromorphic materials in tunable, conformable, ...

FREDERICK, MD, Oct. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to ...

The IBS Center for Neuroscience Imaging has developed a free-standing ion-electron conducting nanomembrane (THIN) that retains structural integrity without external support. When implemented as an ...

FREDERICK, Md.--(BUSINESS WIRE)--BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it filed an application with the U.S ...

EINDHOVEN, Netherlands, Nov. 3, 2020 /PRNewswire/ -- Salvia BioElectronics B.V. ("Salvia"), a neurostimulation platform company targeting chronic migraine, announced today that the U.S. Food and Drug ...

GSK and Verily joint venture Galvani Bioelectronics laparoscopically implanted a neurostimulator in a rheumatoid arthritis (RA) patient as part of the NHS Greater Glasgow & Clyde Health Board’s ...

Researchers at the University of California, Los Angeles have taken a major step in enabling direct fabrication of hydrogel bioelectronics within tissues. Due to their structural similarities with ...

240 Subjects were recruited into 6-month study of 7-day trial users of the ActiPatch medical device to treat chronic pain. 7 days after initial treatment, average pain was reduced by 65%, from 8.2 to ...